Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Pulse from
Precigen, Inc. is set to present its commercial plans for PRGN-2012, a potential FDA-approved treatment for RRP, at the J.P. Morgan Healthcare Conference. The company has completed its BLA submission and is preparing for a potential launch in the second half of 2025. With a cash runway extending into 2026, Precigen is well-positioned financially. The market opportunity for PRGN-2012 in the US is estimated at 27,000 adult patients, with further potential in other HPV-driven indications.
January 13, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen is preparing for the potential launch of PRGN-2012, a treatment for RRP, with a completed BLA submission and financial readiness. The market opportunity is significant, with 27,000 potential patients in the US and further applications in other HPV-driven conditions.
The completion of the BLA submission and the company's financial readiness indicate a strong position for the potential launch of PRGN-2012. The estimated market size and additional applications in other HPV-driven conditions suggest significant revenue potential, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100